Market Overview

LivaNova VNS Therapy System for Drug-Resistant Epilepsy Could Save $77,000 Per Patient Over Five Years


Analysis finds overall cost savings far exceed system-related costs

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company,
today announced that a new cost analysis found the Company's Vagus Nerve
Stimulation Therapy® (VNS Therapy) System results in lower
resource utilization and lower cost for drug-resistant epilepsy (DRE)
patients when compared to continued treatment with anti-epileptic drugs
(AEDs).1 The analysis, published in Advances
in Therapy
and supported by LivaNova, showed initial
costs for the VNS Therapy device, including placement and programming,
were estimated to be offset 1.7 years post-implant and equated to an
estimated net cost savings of $77,480 per patient over five years. The
net cost savings are due primarily to a reduction in seizure-related
hospitalizations, resulting in a 21.5 percent decrease in costs compared
to treatment with AEDs alone.

"The ability to improve outcomes while reducing costs is an important
area of focus in healthcare today. Our VNS Therapy System achieves this
by reducing seizure frequency and by decreasing overall cost of
treatment," said Edward Andrle, LivaNova General Manager of
Neuromodulation. "We are proud that VNS Therapy is a proven, practical
treatment option for drug-resistant epilepsy that eases the associated
financial burden for both patients and the healthcare system."

Approximately one in three patients with epilepsy has DRE. These
patients are subject to frequent seizures that require expensive health
resources like hospitalizations and emergency department visits. By
evaluating more than 1,500 patients in the United States, the new cost
model demonstrates cost savings attributed to positive health outcomes
from the use of VNS Therapy as opposed to treatment with AEDs.

"Not only did the analysis demonstrate a significant cost savings
associated with VNS Therapy treatment in comparison to AED treatment
alone, but this savings is based on a very important health outcome –
the reduction of seizure frequency," said Bryan Olin, LivaNova Senior
Vice President for Clinical, Quality Assurance and Regulatory Affairs.
"By reducing seizure frequency with VNS Therapy, we may also see a
positive impact on patients' quality of life."

About the RTI Health Solutions Study

This study was conducted by RTI Health Solutions under the direction of
LivaNova PLC and was funded by LivaNova PLC. Article processing charges
were funded by LivaNova PLC. The number of eligible patients for the
study was calculated to be 1,536.

About VNS Therapy for Epilepsy

VNS Therapy is clinically proven safe and effective for the treatment of
drug-resistant epilepsy for adults and children. VNS Therapy is designed
to prevent seizures before they occur and stop them if they do. It is a
unique treatment approach developed for people with drug-resistant
epilepsy—a condition that affects one in three people with epilepsy. For
more information, visit


The VNS Therapy System is indicated for use as an adjunctive therapy in
reducing the frequency of seizures in patients 4 years of age and older
with partial onset seizures that are refractory to antiepileptic

Individual results may vary. Common side effects include hoarseness,
shortness of breath, sore throat and coughing. To view safety and full
prescribing information, visit

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five
decades of experience and a relentless commitment to improve the lives
of patients around the world. LivaNova's advanced technologies and
breakthrough treatments provide meaningful solutions for the benefit of
patients, healthcare professionals and healthcare systems. Headquartered
in London, LivaNova has a presence in more than 100 countries worldwide.
The Company currently employs approximately 4,000 employees.
LivaNova operates as two businesses: Cardiac Surgery and
Neuromodulation, with operating headquarters in Mirandola (Italy)
and Houston (U.S.A.), respectively.

For more information, please visit

Safe Harbor Statement

This news release contains forward-looking statements within the meaning
of Section 27A of the United States Securities Act of 1933, as amended,
and Section 21E of the United States Securities Exchange Act of 1934, as
amended. Forward-looking statements are not historical facts but are
based on certain assumptions of management and describe LivaNova's
future plans, strategies and expectations. Forward-looking statements
can generally be identified by the use of forward-looking terminology,
including, but not limited to, "may," "could," "seek," "guidance,"
"predict," "potential," "likely," "believe," "will," "expect,"
"anticipate," "estimate," "plan," "intend," "forecast," or variations of
these terms and similar expressions, or the negative of these terms or
similar expressions. Forward-looking statements contained in this news
release are based on information presently available to LivaNova and
assumptions that LivaNova believes to be reasonable, but are inherently
uncertain. As a result, LivaNova's actual results, performance or
achievements may differ materially from those expressed or implied by
these forward-looking statements, which are not guarantees of future
performance or actions that may be taken by LivaNova and involve known
and unknown risks, uncertainties and other factors that are, in some
cases, beyond LivaNova's control. You should carefully consider the
risks and uncertainties that affect LivaNova, including those described
in the "Risk Factors" section of LivaNova's Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other
documents filed from time to time with the United States Securities and
Exchange Commission.

All information in this news release is as of the date of its release.
LivaNova does not undertake or assume any obligation to update publicly
any of the forward-looking statements in this news release to reflect
actual results, new information or future events, changes in assumptions
or changes in other factors affecting forward-looking statements, except
to the extent required by applicable law. If we update one or more
forward-looking statements, no inference should be drawn that we will
make additional updates with respect to those or other forward-looking
statements. We caution you not to place undue reliance on any
forward-looking statements, which are made only as of the date of this
news release.

1 Purser, M.F., Mladsi, D.M., Beckman, A. et al.
Adv Ther (2018).
The New England Journal of Medicine. Drug-Resistant Epilepsy. Patrick
Kwan, M.D., Ph.D., Steven C. Schachter, M.D., and Martin J. Brodie, M.D.

View Comments and Join the Discussion!